Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Revenues:
Product sales, net	$ 16,981,000	$ 6,545,000
Research and development income	1,094,000	1,931,000
Licensing, royalty and other income	149,000	87,000
Total revenues	18,224,000	8,563,000
Costs and Expenses:
Cost of sales	12,079,000	5,787,000
Selling, general and administrative expenses	3,484,000	3,078,000
Product development and research expenses	2,743,000	2,834,000
Total costs and expenses	18,306,000	11,699,000
Operating loss	(82,000)	(3,136,000)
Interest expense and other income (expense), net	(199,000)	(975,000)
Loss before benefit from income taxes	(281,000)	(4,111,000)
Benefit from income taxes, principally sale of New Jersey net operating losses	197,000	184,000
Net loss	(84,000)	(3,927,000)
Deemed dividend upon mandatory conversion of preferred stock into common stock	(1,308,000)
Net loss attributable to common stockholders	$ (1,392,000)	$ (3,927,000)
Basic and diluted loss per common share (in Dollars per share)	$ (0.03)	$ (0.10)
Weighted average shares of common stock outstanding
Basic and diluted (in Shares)	43,517,640	39,786,446